RT Journal Article
SR Electronic
T1 OP018/#414 Progression free survival and overall survival after BRCA1/2-ASSOCIATED epithelial ovarian cancer: a matched cohort study
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A18
OP A19
DO 10.1136/ijgc-2021-IGCS.35
VO 31
IS Suppl 4
A1 B Heemskerk-Gerritsen
A1 A Hollestelle
A1 I Van Den Beek
A1 W Van Driel
A1 K Van Engelen
A1 E Gómez Garcia
A1 J De Hullu
A1 M Koudijs
A1 M Mourits
A1 M Hooning
A1 I Boere
YR 2021
UL http://ijgc.bmj.com/content/31/Suppl_4/A18.2.abstract
AB Objectives BRCA1/2-associated epithelial ovarian cancer (EOC) has been associated with better progression-free survival (PFS) and overall survival (OS) than sporadic EOC. Higher sensitivity to chemotherapy may be an explanation, but data are scarce.Methods We matched 512 BRCA1/2-associated EOC patients selected from the national Hereditary Breast and Ovarian Cancer Netherlands (HEBON) database to 512 sporadic EOC patients from the National Cancer Registry on year of birth, year of EOC diagnosis (range 1989–2015), and FIGO stage (≤IIA/≥IIB). All patients were treated with chemotherapy. We used Cox models with the sporadic group as the reference to obtain hazard ratios (HR) with corresponding 95% confidence intervals (CI). Since BRCA1/2 mutation carriers who received a DNA test after EOC diagnosis survived at least until this DNA test, which may result in survival bias, we also performed prospective analyses including only BRCA1/2-associated EOC patients with a DNA test result before EOC diagnosis (n=82) and their matched sporadic controls.Results The mean follow-up was 4.4 years (range 0.1–30.1). For the first 5 years after EOC diagnosis, the HRs for PFS (0.85, 95% CI 0.73–0.98) and OS (0.58, 95% CI 0.49–0.69) were in favor of the BRCA1/2 EOC patients. In the prospective analyses, survival benefit withstand for PFS (HR 0.66, 95% CI 0.45–0.98), and – to a lesser extent – for OS (HR 0.69, 95% CI 0.44–1.1).Conclusions For EOC patients treated with chemotherapy, we confirmed survival benefit for BRCA1/2 mutation carriers. This may indicate higher sensitivity to chemotherapy, both in first line treatment and in the recurrent setting.